Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
This study is a card Rayleigh bead single combined cisplatin treatment of advanced squamous cell carcinoma of the skin resistance of single arm phase II study, open, single center, plan in two years into the group of 20 cases with histologic diagnosis of lymph node metastasis or distant metastasis CSCC of (1) or surgery can't/couldn't thorough radiotherapy, CSCC of locally advanced (class 2), To evaluate the efficacy of camrelizumab (PD-1 mab) combined with cisplatin in the treatment of advanced CSCC.
Squamous Cell Carcinoma of the Skin
DRUG: Camrelizumab
Progression-free survival, From initiation of treatment to progression of the disease, Up to approximately 24months|Overall survival, Time from the start of treatment to death, Up to approximately 120months
This study is a card Rayleigh bead single combined cisplatin treatment of advanced squamous cell carcinoma of the skin resistance of single arm phase II study, open, single center, plan in two years into the group of 20 cases with histologic diagnosis of lymph node metastasis or distant metastasis CSCC of (1) or surgery can't/couldn't thorough radiotherapy, CSCC of locally advanced (class 2), To evaluate the efficacy, safety and quality of life of patients with advanced CSCC treated with camrelizumab (PD-1 mab) combined with cisplatin.